Compare iShares MSCI South Korea ETF (EWY) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Summit Therapeutics Inc — how do they compare? iShares MSCI South Korea ETF trades at $163.2, while Summit Therapeutics Inc trades at $13.84 (market cap $11.70B). The key difference: iShares MSCI South Korea ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| EWY | SMMT | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $29.32 |
52-Week Low | $70.65 | $13.05 |
Market Cap | — | $11.70B |
Enterprise Value | — | $11.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY is trading at $163.67, down 7.52% with significant volatility driven by its heavy concentration in South Korean semiconductor giants Samsung and SK Hynix. The ETF has entered bear market territory, reflecting global tech sector pressures and foreign investor selling. Technical indicators show bearish momentum with RSI near oversold levels at 28, while support sits at $157. Recent news highlights the Kospi Index's 21% decline from YTD highs, creating both risk and potential opportunity.
The outlook remains challenged by semiconductor cycle volatility and concentrated exposure, but long-term AI demand fundamentals provide potential upside. Key risks include single-stock concentration, foreign capital flows, and global tech sentiment shifts. Investors should weigh near-term volatility against structural semiconductor growth drivers.
Summit Therapeutics (SMMT) trades at $13.90, down 10.15% today, reflecting market reaction to mixed earnings and high volatility. The technical picture is bearish with weak moving averages, while fundamentals show significant losses with a net income of -$1.08B in 2025 and negative ROE/ROA. Recent news includes a $105M divestiture of ridinilazole to Biossil, sharpening focus on oncology, and upcoming Q2 2026 results on July 23, 2026.
Outlook hinges on clinical success of ivonescimab, with a bullish analyst consensus (66.7% buy ratings) and $15.57 price target suggesting 12% upside. Key risks include binary drug trial outcomes, cash burn from negative operating cash flow, and high short interest creating volatility. Investors face a high-risk, catalyst-driven opportunity dependent on pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
